🧬 BioMed Pulse · 2026-11-08 02:01 UTC

BIOMED PULSE

Sunday, November 8, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has spread to Kenya and Nigeria, making it the largest Ebola outbreak ever recorded in the DRC and still intensifying with no end in sight. [1] Overall mood: urgent and sobering — a historic hemorrhagic fever crisis demands global attention while other outbreak fronts remain active.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC, KENYA, NIGERIA

  • As of October 23, 2026, the Bundibugyo virus disease (BVD) outbreak in DRC has expanded geographically into Kenya and Nigeria via imported cases, marking a significant widening of the epidemic's footprint. [1]
  • WHO's Disease Outbreak News DON622 confirms sustained, high-level transmission in DRC remains the engine driving regional spread; the DRC outbreak is already described as the largest Ebola outbreak ever reported in the country, expanding faster than any previous Ebola event. [2][1]
  • As of August 14, 2026 (DON615), the outbreak had spread to 54 health zones; by August 28 (DON616) it had reached 60 health zones across six provinces — Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [3]
  • Cross-border transmission to Uganda was confirmed early in the outbreak; an imported case in Kenya was laboratory-confirmed on October 5, 2026, with travel history from DRC through Uganda. [4]
  • CDC has previously activated enhanced Ebola airport screening at Washington-Dulles International Airport and Atlanta in response to this outbreak. [5][6]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • On October 2, 2026, WHO received media reports of the death of an employee at the Irkutsk Antiplague Research Institute of Siberia and the Far East, Russian Federation, following severe pneumonia. [7]
  • The etiology remains undetermined; WHO posted this as DON620, flagging the institutional connection to a biosafety-relevant laboratory setting as a factor requiring follow-up. [7]

MERS-CoV — SAUDI ARABIA

  • Between January 1 and October 5, 2026, Saudi Arabia reported eight laboratory-confirmed cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), including one death, detected across six locations including Riyadh, Tabuk, and Al Jouf. [8]
  • MERS-CoV continues to circulate at a low but persistent endemic level in the Arabian Peninsula; camel exposure remains the primary zoonotic risk factor in these settings. [8]

LISTERIA — PREPARED MEALS (U.S.)

  • CDC is continuing to urge consumers to check refrigerators and freezers for recalled prepared foods linked to an ongoing Listeria outbreak; new illnesses have been reported even after product recalls. [9]
  • The outbreak has been expanded multiple times to include additional prepared meal products; at least one additional death has been linked since the September 26 expansion. [10]

SALMONELLA — MORINGA LEAF PRODUCTS (U.S.)

  • An extensively drug-resistant Salmonella strain linked to moringa powder capsules remains active; as of January 29, 2026, 65 people across 28 states had been infected, with three hospitalizations reported.
  • CDC issued a growing-alert update in May 2026 flagging an increasing number of Salmonella illnesses and outbreaks tied to moringa leaf products broadly, not just capsules.

DRUG-RESISTANT BACTERIA

  • A September 2025 CDC report documented a dramatic increase in dangerous drug-resistant bacteria, signaling a worsening antimicrobial resistance landscape in the United States.

🧬 LONGEVITY & AGING

COGNITIVE AGING AND PSILOCYBIN-ASSISTED TRAINING

  • A new ClinicalTrials.gov-registered study (NCT07721467) is investigating whether psilocybin combined with regular cognitive training can enhance neuroplasticity in older adults experiencing normal aging-related cognitive decline or early dementia including Alzheimer's disease.
  • The trial targets brain changes that impair memory, attention, and thinking in aging, exploring whether the psychedelic compound can amplify the structural benefits of mental exercise.

ACUPRESSURE FOR EARLY ALZHEIMER'S DISEASE

  • A randomized controlled trial (NCT07779863) is enrolling 188 adults aged 60 to 85 with early or mild Alzheimer's disease from care homes and elderly activity centers to test whether sustained acupressure intervention can slow disease progression.
  • The assessor-blinded design aims to provide rigorous evidence for a low-cost, non-pharmacological intervention in a population where disease-modifying options remain limited.

PERSONALIZED NUTRITION FOR OLDER ADULTS

  • A ClinicalTrials.gov study (NCT06163794) is investigating multidimensional phenotyping — accounting for age, sex, genotype, gut microbiota, eating behavior, and physical activity — to build personalized preventive nutritional support strategies for elderly individuals.
  • Researchers cite high inter-individual variability in responses to feeding as the core motivation for moving beyond population-level dietary guidance toward precision nutrition in aging.

INSOMNIA IN OLDER ADULTS

  • A nurse-led brief behavioral therapy for insomnia (BBTi) trial (NCT06073990) is underway in middle-aged and older adults with chronic insomnia, aiming to assess whether a structured short-course behavioral approach can durably improve sleep health in this age group.
  • Sleep disruption is a recognized contributor to accelerated biological aging, dementia risk, and metabolic dysfunction, making this trial relevant to the broader geroscience field.

GERIATRIC ONCOLOGY CARE PATHWAY

  • The GERONTE study (NCT05720910), a stepped-wedge randomized controlled trial across multiple hospitals in France, is evaluating an ICT-based integrated care pathway designed to improve 6-month quality of life for older cancer patients.
  • The trial targets the gap between standard oncology protocols and the specific frailty and multimorbidity profiles of elderly patients requiring individualized geriatric-oncological coordination.

CANCER MORTALITY TRENDS

  • A September 2026 CDC report to the nation on cancer trends highlighted that progress against lung cancer is driving overall cancer mortality declines in the United States.

💊 NEW CURES & APPROVALS

ORGOVYX SUPPLEMENTAL APPROVAL — SUMITOMO PHARMA AMERICA

  • The FDA recorded a supplemental approval (SUPPL AP) for Orgovyx (relugolix), sponsored by Sumitomo Pharma America, NDA214621; relugolix is an oral GnRH receptor antagonist indicated for advanced prostate cancer.

ZYNLONTA SUPPLEMENTAL APPROVAL — ADC THERAPEUTICS SA

  • A supplemental approval was recorded for Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate sponsored by ADC Therapeutics SA, BLA761196; it targets relapsed or refractory diffuse large B-cell lymphoma.

RELEUKO SUPPLEMENTAL APPROVAL — KASHIV BIOSCIENCES

  • Releuko (filgrastim-ayow), a granulocyte colony-stimulating factor biosimilar sponsored by Kashiv Biosciences LLC, received a supplemental approval under BLA761082; it is used to reduce infection risk from severe neutropenia in chemotherapy patients.

HYDROXYUREA — ESJAY PHARMA (NEW ORIGINAL APPROVAL)

  • An original approval (ORIG AP) was recorded for a hydroxyurea formulation from Esjay Pharma, ANDA220300; hydroxyurea is used to treat sickle cell disease and certain cancers by inhibiting DNA synthesis.

FLUTICASONE PROPIONATE — TEVA PHARMACEUTICALS USA

  • An original approval was recorded for a fluticasone propionate formulation (ANDA209917) by Teva Pharms USA Inc, an inhaled corticosteroid used for asthma and allergic rhinitis.

PROPOFOL — BAXTER HEALTHCARE CORP

  • An original approval was recorded for a propofol injectable formulation (ANDA203421) by Baxter Healthcare Corp, an intravenous anesthetic agent used for procedural sedation.

NOTE: All openFDA items above reflect regulatory approval actions; dates were not available in source records. These are not new molecular entities in all cases but represent new manufacturing approvals expanding supply access.

🧪 CLINICAL TRIALS

PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID — PHASE I

  • A Phase I open-label safety trial (NCT07388550) opened November 6, 2026, is testing pembrolizumab — a PD-1 checkpoint inhibitor — in patients with neurological post-acute sequelae of SARS-CoV-2 (neuro-PASC), including symptoms such as headaches, loss of smell or taste, dizziness, and difficulty walking.
  • The mechanistic rationale is that PD-1 pathway dysregulation may sustain chronic neuroinflammation in long COVID; this is among the first immune checkpoint trials targeting neuro-PASC specifically.

RSV VACCINE IMMUNE RESPONSE IN OLDER ADULTS — CHINA VS. OVERSEAS COHORT

  • A study (NCT06551181) is evaluating the immune response, safety, and RSV-associated respiratory illness incidence following the RSVPreF3 OA adjuvanted vaccine in adults aged 60 and older in China, compared to overseas participants from a prior global trial.
  • RSV causes disproportionate severe illness in older adults, and this comparative immunogenicity data could support regulatory decisions in Asian populations.

ACUPRESSURE FOR MILD ALZHEIMER'S — RANDOMIZED CONTROLLED TRIAL

  • The trial (NCT07779863) recruiting 188 adults aged 60 to 85 across elderly care homes will assess acupressure as a non-pharmacological intervention to slow early Alzheimer's disease progression, with randomized allocation and blinded assessment.

PSILOCYBIN PLUS COGNITIVE TRAINING — NEUROPLASTICITY IN AGING

  • Trial NCT07721467 is investigating psilocybin's capacity to enhance the neuroplasticity gains of cognitive training in older adults and Alzheimer's patients, at the NIH.

PERIODONTAL DISEASE AND LIVER HEALTH LINK

  • A prospective observational study (NCT07923409) at Recep Tayyip Erdogan University in Turkey is examining the relationship between periodontal status, oral biomarkers, and metabolic dysfunction-associated steatotic liver disease (MASLD), a condition closely tied to aging and metabolic syndrome.

📢 PUBLIC HEALTH

LISTERIA RECALL ALERT — PREPARED MEALS STILL IN HOMES

  • CDC is urging all households to check refrigerators and freezers for recalled prepared meals linked to the ongoing Listeria outbreak; the agency warns illnesses are continuing despite prior recalls, suggesting recalled products remain in circulation. [9]

SALMONELLA — MULTIPLE ACTIVE OUTBREAKS

  • Active CDC-tracked Salmonella outbreaks currently include links to moringa leaf supplement capsules (extensively drug-resistant strain, 28 states) and backyard poultry (with over one-quarter of cases in children under 5).

HEPATITIS B IMMUNIZATION POLICY SHIFT

  • CDC adopted individual-based decision-making for hepatitis B immunization for infants born to mothers who test negative for hepatitis B virus, replacing the previous universal birth-dose recommendation for that specific population.

ANIMAL RABIES AND HUMAN EXPOSURE INCREASE

  • A September 2026 CDC statement flagged a recent sharp rise in animal rabies activity and associated human exposures, prompting a public advisory for anyone who may have been in contact with potentially rabid animals to seek prompt post-exposure prophylaxis.

TICK BITE ER VISITS ABOVE SEASONAL NORM

  • CDC reported in April 2026 that weekly emergency department visits for tick bites were running higher than usual for the season, urging the public to use repellents and perform tick checks.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
  8. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
  9. CDC continues to note illnesses despite product recalls and as… — CDC Newsroom
  10. CDC expands Listeria outbreak to include more prepared meals — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261108-02-v130 · 2026-11-08 02:01 UTC · pulse.uzylab.com